R1	AND Arg1:T4 Arg2:T5	
R2	Has_qualifier Arg1:T4 Arg2:T2	
R3	Has_qualifier Arg1:T4 Arg2:T3	
R4	Has_mood Arg1:T6 Arg2:T7	
R5	AND Arg1:T4 Arg2:T6	
R6	Has_value Arg1:T8 Arg2:T9	
R7	Has_qualifier Arg1:T12 Arg2:T11	
R8	Has_qualifier Arg1:T12 Arg2:T10	
R9	Has_value Arg1:T14 Arg2:T15	
R10	Has_value Arg1:T16 Arg2:T17	
R11	Has_value Arg1:T18 Arg2:T19	
T1	Informed_consent 0 81	Has given written informed consent before any study-related activity is performed
T2	Qualifier 92 109	hormone-dependent
T3	Qualifier 83 91	Advanced
T4	Condition 110 125	prostate cancer
T5	Procedure 136 164	androgen deprivation therapy
T6	Drug 214 222	Firmagon
T7	Mood 227 235	intended
T8	Person 262 265	Age
T9	Value 266 322	greater than or equal to 18 years and less than 80 years
T10	Qualifier 324 332	Advanced
T11	Qualifier 333 350	hormone-dependent
T12	Condition 351 366	prostate cancer
T13	Non-query-able 367 416	without any other clinically significant disorder
T14	Measurement 418 457	Easten Cooperative Oncology Group score
T15	Value 458 461	= 2
T16	Measurement 463 466	PSA
T17	Value 467 476	= 2 ng/mL
T18	Observation 491 506	Life expectancy
T19	Value 510 528	at least 12 months
